OGN - Some Q3 pharma stock superstars start Q4 off on wrong foot

Moderna (NASDAQ:MRNA), BioNTech (NASDAQ:BNTX), and Regeneron Pharmaceuticals (NASDAQ:REGN), respectively, the first, second, and fifth best performing pharma stocks of Q3 have not continued that positive momentum early in Q4. Since Oct. 1 through the close of trading today, Moderna is down ~16%, BioNTech has lost 6%, and Regeneron is down 5%. Moderna and BioNTech shares were hit on Oct. 1 from data on Merck's (MRK -1.2%) antiviral pill molnupiravir showing a 50% risk reduction in hospitalization and death. Regeneron, who manufactures the COVID antibody therapy REGEN-COV (casirivimab and imdevimab), also saw its shares pressured on the news. Merck is down 1% so far in the quarter. Novo Nordisk (NYSE:NVO) and Organon (NYSE:OGN), respectively, the third and fourth best performing stocks in Q3, are up modestly in Q4.

For further details see:

Some Q3 pharma stock superstars start Q4 off on wrong foot